Melanoma is the deadliest form of skin cancer, arising from melanocytes, the pigment-producing cells found primarily in the skin but also in the eyes and mucous membranes. Although it accounts for a small fraction of all skin cancers, melanoma is responsible for the majority of skin-cancer deaths because of its ability to spread aggressively to distant organs. What makes melanoma particularly complex is that it is not a single disease: it encompasses several subtypes driven by distinct genetic mutations, and it can appear in places that never see sunlight. Treatment has undergone a revolution over the past decade, but the biology of melanoma still holds surprises that shape who gets it, how it is caught, and how well therapy works.
How UV Radiation Damages Melanocytes
Ultraviolet radiation is the most important environmental cause of cutaneous melanoma. When UV light strikes skin cells, it can directly damage DNA by creating abnormal bonds between neighboring bases in the genetic code. But the damage does not stop when you step out of the sun. Research on melanocytes shows that UVA exposure triggers a second wave of DNA damage hours afterward, driven by reactive molecules like nitric oxide and superoxide that the cells themselves generate. In lab experiments, this delayed damage peaked a full 24 hours after UVA exposure, meaning the injury to melanocyte DNA continues long after the sunburn starts to fade.1MDPI Antioxidants. Formation of Cyclobutane Pyrimidine Dimers after UVA Exposure (Dark-CPDs) Is Inhibited by an Hydrophilic Extract of Polypodium leucotomos – Section: 3. Results / 3.3. Dark-CPD Formation That delayed, “dark” DNA damage helps explain why a single bad sunburn can have consequences that unfold over years: accumulated mutations in key growth-regulating genes eventually push a melanocyte toward uncontrolled division.
The Genetic Drivers Behind Melanoma Growth
Not all melanomas carry the same mutations. In a community-based study of over 400 cutaneous melanomas, researchers found that about a quarter carried the BRAF V600E mutation, roughly 8% had BRAF V600K, and about 9% harbored NRAS mutations, with these mutations appearing in a mutually exclusive pattern.2PubMed. Histologic and Phenotypic Factors and MC1R Status Associated with BRAF(V600E), BRAF(V600K), and NRAS Mutations in a Community-Based Sample of 414 Cutaneous Melanomas These mutations sit in growth-signaling pathways that tell the cell to keep dividing. Knowing which mutation a tumor carries is now central to choosing treatment, because therapies that block BRAF work only when that particular mutation is present.
For melanomas that arise outside the skin, the genetic picture shifts dramatically. Uveal melanoma, which develops in the eye, is driven almost entirely by mutations in two related genes, GNAQ and GNA11, rather than BRAF or NRAS. In one cohort of metastatic uveal melanomas, over 96% carried a hotspot mutation in one of those two genes.3American Journal of Clinical Pathology. Genomic Profiling of Metastatic Uveal Melanoma Shows Frequent Coexisting BAP1 or SF3B1 and GNAQ/GNA11 Mutations and Correlation With Prognosis Additional changes, including loss of chromosome 3 and mutations in the tumor-suppressor gene BAP1, strongly influence whether uveal melanoma will metastasize.4PubMed Central. The biology of uveal melanoma Patients whose uveal tumors carry GNA11 mutations appear to face worse survival than those with GNAQ mutations, a finding that underscores how even closely related mutations can carry very different prognoses.5PubMed. Genetic and clinico-pathologic analysis of metastatic uveal melanoma
Acral melanoma, the type that forms on palms, soles, and nail beds, and mucosal melanoma, which develops on internal mucous membranes, have their own genetic signatures. Acral melanomas more commonly carry amplifications in genes like PAK1 and GAB2, while mucosal melanomas show unique mutations in the splicing factor SF3B1.6PubMed Central. Integrated genomic analyses of acral and mucosal melanomas nominate novel driver genes These subtypes are particularly important for people with darker skin tones, in whom acral melanoma accounts for a disproportionate share of melanoma diagnoses, often at a later stage because neither patients nor physicians think of melanoma in that setting.
Who Is Most at Risk
The strongest single risk factor for cutaneous melanoma is ultraviolet exposure, but your underlying biology matters enormously. People with red hair and fair skin carry polymorphisms in the MC1R gene that shift pigment production away from the protective dark pigment eumelanin and toward pheomelanin, the reddish-yellow pigment that is far less effective at blocking UV. What is striking is that pheomelanin itself appears to actively promote melanoma formation. In mouse experiments, animals engineered to produce high levels of pheomelanin developed melanomas at elevated rates even without UV exposure, while albino mice that lacked all pigment did not.7Cancer Discovery. Red Hair/Fair Skin Pigmentation Directly Enhances Melanoma Incidence This suggests pheomelanin itself generates oxidative damage inside melanocytes, adding to whatever harm UV light causes from the outside.8PubMed. Pheomelanin-induced oxidative stress: bright and dark chemistry bridging red hair phenotype and melanoma
A high number of moles, a history of blistering sunburns in childhood, and intermittent intense sun exposure (think beach holidays rather than daily outdoor work) all push risk upward. Family history adds another layer. If multiple close relatives have had melanoma, the risk becomes substantially harder to explain by shared sun habits alone.
Familial Melanoma and Inherited Gene Mutations
Roughly 5 to 10% of melanoma cases cluster in families. The gene most commonly implicated is CDKN2A, a tumor suppressor that normally helps cells stop dividing when they should. Germline mutations in CDKN2A show up in about 20 to 40% of families with a strong melanoma history, and carriers tend to develop melanoma at younger ages, sometimes multiple primary tumors, and face an elevated risk of pancreatic cancer as well.9PubMed Central. Familial Melanoma: Diagnostic and Management Implications CDKN2A mutations have also been linked to increased risk of tobacco-related cancers in the respiratory and upper digestive tract.10JNCI: Journal of the National Cancer Institute. Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases
Other high-penetrance genes, including CDK4, BAP1, and POT1, are rarer but carry pronounced risk. Medium- and low-penetrance variants like certain MC1R polymorphisms contribute only moderately on their own but can amplify risk when combined with sun exposure or other genetic hits.11PubMed. Unveiling the genetic landscape of hereditary melanoma: From susceptibility to surveillance If you have two or more first-degree relatives with melanoma, or a personal history of melanoma before age 40, genetic counseling can help determine whether testing for CDKN2A or related genes makes sense. A positive result would not change the recommended screening tools, but it would likely increase how often you are examined and how aggressively suspicious spots are biopsied.
How Melanoma Is Detected
The familiar ABCDE rule (Asymmetry, Border irregularity, Color variation, Diameter above 6 mm, Evolving) remains a useful mental checklist for patients watching their own skin. But in a clinical setting, dermoscopy, which uses a handheld magnifying device with polarized light, significantly outperforms the naked eye. A Cochrane review found dermoscopy to be roughly five times more accurate than visual inspection alone for diagnosing melanoma.12Cochrane Database of Systematic Reviews. Dermoscopy, with and without visual inspection, for the diagnosis of cutaneous melanoma Dermatologists use several structured scoring methods to interpret dermoscopic images. In an international comparison, the Menzies method had the highest sensitivity for catching melanoma (about 95%), though at the cost of lower specificity, meaning it flagged more benign lesions as suspicious.13JAMA Dermatology. Validity and Reliability of Dermoscopic Criteria Used to Evaluate Pigmented Lesions: The International Dermoscopy Society Study Primary care physicians also benefit from dermoscopy training, because it improves their assessments of worrying lesions beyond what the unaided eye achieves.14PubMed Central. Using Dermoscopy to Identify Melanoma and Improve Diagnostic Discrimination
Artificial intelligence is rapidly entering this space. A large meta-analysis found that AI systems collectively achieved about 89% sensitivity and 92% specificity for melanoma diagnosis, with hybrid models combining multiple algorithmic approaches performing best.15PubMed Central. Diagnosis melanoma with artificial intelligence systems: A meta‐analysis study and systematic review In real-world primary care, one AI-powered smartphone app achieved 95% sensitivity for melanoma overall and 100% sensitivity for invasive melanomas in a prospective trial of 253 lesions.16PubMed. Evaluation of an artificial intelligence-based decision support for the detection of cutaneous melanoma in primary care: a prospective real-life clinical trial Those numbers are encouraging, but the trial was small, and AI performance can vary across skin tones and lesion types that are underrepresented in training data. For now, AI tools serve best as a second opinion that flags lesions for a dermatologist to evaluate rather than as standalone diagnostic devices.
Staging and the Sentinel Lymph Node Debate
Once melanoma is confirmed by biopsy, staging determines how far the cancer has spread. The single most important measurement is Breslow depth, the thickness of the tumor in millimeters. Whether the surface is ulcerated also matters. For tumors above a certain thickness, a sentinel lymph node biopsy has traditionally been performed: a surgeon identifies the first lymph node that drains the tumor site, removes it, and checks for cancer cells. A positive node generally signals a worse prognosis and may change treatment decisions.17PubMed Central. Redesigning Sentinel Lymph Node Biopsy Guidelines in Melanoma Cases
The value of this procedure, however, has become contested. One analysis found that sentinel node status did not provide independent prognostic information beyond what Breslow thickness alone could supply, meaning that within each thickness group, survival differences between node-positive and node-negative patients were not statistically significant.18Journal of the American Academy of Dermatology. Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma This does not mean the procedure is useless, but guidelines are evolving. For thin melanomas (under 1 mm), sentinel node biopsy is increasingly reserved for cases with ulceration or other high-risk features, sparing many patients a surgical procedure with its own risks of lymphedema and discomfort.
Targeted Therapy for BRAF-Mutant Melanoma
For patients whose melanoma carries a BRAF V600 mutation, drugs that directly block the faulty BRAF protein have transformed outcomes. The standard approach pairs a BRAF inhibitor (dabrafenib) with a MEK inhibitor (trametinib) because combining the two is more effective than BRAF blockade alone. In a head-to-head trial, the combination produced a response rate of about 67% versus 51% with dabrafenib alone.19PubMed. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Used after surgery for stage III BRAF-mutated melanoma, the combination also delays recurrence. The three-year relapse-free survival rate was about 58% with therapy versus 39% with placebo.20PubMed. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma For metastatic disease, long-term pooled data show that about a third of patients treated with the combination remain alive at five years, a figure that was essentially unheard of before these drugs existed.21PubMed. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
The major limitation is resistance. About one in five patients never responds at all, and among those who do, most eventually see their tumor restart growth. Resistance arises through several routes: the tumor can reactivate the very signaling pathway the drugs were blocking, switch to alternate growth pathways, or ramp up receptors on the cell surface that bypass BRAF entirely.22PubMed Central. Resistant mechanisms to BRAF inhibitors in melanoma Some tumors undergo broader cellular changes that make them behave more like invasive, migratory cells.23PubMed Central. Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review This is why clinical strategies often involve sequencing targeted therapy with immunotherapy, or combining them, to stay ahead of the tumor’s adaptive machinery.
Immunotherapy and the Checkpoint Revolution
Melanoma was one of the first cancers where immunotherapy proved its power. Drugs called checkpoint inhibitors work by releasing the brakes that tumors place on the immune system. The two main classes used in melanoma block either PD-1 (pembrolizumab, nivolumab) or CTLA-4 (ipilimumab). Combining the two is more potent than either alone, but the combination comes with higher toxicity. A trial of standard-dose pembrolizumab with reduced-dose ipilimumab demonstrated strong and durable responses with more manageable side effects than full-dose combinations.24Clinical Cancer Research. Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
Finding the right dosing balance has been a persistent challenge. Several trials have compared different dose ratios of nivolumab and ipilimumab and found similar efficacy between regimens, but higher ipilimumab doses trend toward more severe side effects without clear survival benefits.25PubMed Central. Adverse events induced by nivolumab and ipilimumab combination regimens The side effects can be serious, including inflammation of the colon, liver, lungs, thyroid, and other organs, because the immune system, once unleashed, does not always limit its attack to the tumor. Managing these toxicities requires careful monitoring, and for some patients the side effects are severe enough to stop treatment early.
One of the most intriguing findings in recent years is that the gut microbiome influences how well checkpoint inhibitors work. A study of melanoma patients receiving anti-PD-1 therapy found that responders had significantly higher gut bacterial diversity and were enriched for certain bacterial families compared with nonresponders. When fecal material from responders was transplanted into germ-free mice, those mice showed enhanced antitumor immunity.26PubMed Central. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients This line of research is still early, but it raises the possibility that future treatment strategies may include deliberately modifying gut bacteria to improve immunotherapy outcomes.
Tumor-Infiltrating Lymphocyte Therapy
For patients whose melanoma progresses through both targeted therapy and checkpoint inhibitors, options have historically been bleak. That changed in February 2024 when the FDA granted accelerated approval to lifileucel, the first commercially available tumor-infiltrating lymphocyte (TIL) therapy, and the first cellular therapy approved for any solid tumor.27PubMed Central. Tumor-Infiltrating Lymphocyte Therapy for the Treatment of Metastatic Melanoma The approach involves surgically removing a piece of tumor, isolating the immune cells already present within it, expanding them to billions in a lab, and infusing them back into the patient.
TIL therapy has shown consistent response rates near 50% across multiple trials spanning decades.28PubMed Central. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook A randomized trial comparing TIL therapy head-to-head with ipilimumab in patients with advanced melanoma found a median progression-free survival of about 7 months for TIL versus 3 months for ipilimumab, with response rates of 49% versus 21%.29PubMed. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma TIL therapy’s key advantage over engineered T-cell approaches is that the infused cells recognize a broad range of tumor targets rather than a single pre-selected one, making it harder for the tumor to escape by losing one protein.
The downsides are significant: the manufacturing process takes weeks, patients need intensive pretreatment chemotherapy to clear existing immune cells, and TIL therapy is currently available only at specialized centers. Research on personalized mRNA vaccines designed to train the immune system against a patient’s specific tumor mutations represents another emerging approach, though these remain in clinical trials for melanoma.
Sunscreen, Prevention, and the Screening Controversy
Regular sunscreen use is one of the few interventions with direct evidence of reducing melanoma incidence. A landmark randomized trial found that consistent sunscreen application cut melanoma rates by about half compared with discretionary use, and the benefit persisted even after the trial ended.30PubMed Central. The efficacy and safety of sunscreen use for the prevention of skin cancer Broad-spectrum sunscreen with SPF 30 or higher, applied properly and reapplied every couple of hours during sustained outdoor exposure, is the standard recommendation. Protective clothing, seeking shade during peak UV hours, and avoiding indoor tanning all complement sunscreen use.
Population-wide skin cancer screening, on the other hand, is more controversial than most people assume. A Cochrane review found no randomized controlled trial evidence to support or refute general-population screening for melanoma.31Cochrane Database of Systematic Reviews. Screening for malignant melanoma Observational data from large cohorts show that screened individuals are diagnosed with more in-situ (very early, noninvasive) melanomas but not more invasive melanomas, raising the concern that screening may primarily detect tumors that would never have caused harm.32British Journal of Dermatology. The effect of screening on melanoma incidence and biopsy rates Germany’s nationwide skin-cancer screening program has not been associated with a significant decline in melanoma death rates compared with regions that lack such a program.33PubMed Central. Population Skin Cancer Screening and Melanoma Mortality Rates
This does not mean you should skip skin checks. For individuals with strong risk factors, including a family history of melanoma, many atypical moles, fair skin with a history of blistering sunburns, or a known genetic predisposition, regular dermatologist visits are well justified. The evidence gap is specifically about screening everyone, not about examining people at higher risk.
Sex Differences in Melanoma Outcomes
Men and women experience melanoma differently in ways that go beyond behavior. Men are more likely to be diagnosed with thicker tumors and have worse survival rates at every stage. While it is true that women are generally more proactive about seeking medical care, behavioral differences alone do not fully account for the gap. Research increasingly points to biological explanations, including differences in immune system function between the sexes and the role of sex hormones. Estrogen receptor signaling appears to be inversely associated with tumor aggressiveness, while testosterone may enhance it. Mouse studies suggest that newer immunotherapies may actually work more effectively in females.34PubMed Central. Sex Differences in Melanoma If confirmed in larger human studies, these findings could eventually inform sex-specific treatment strategies, though clinical practice has not yet moved in that direction.
The Tumor Microenvironment and Why It Matters for Treatment
Melanoma does not grow in isolation. The tissue surrounding a tumor, called the tumor microenvironment, contains fibroblasts, immune cells, blood vessels, and a mesh of structural proteins that the tumor actively remodels to support its own growth. Cancer-associated fibroblasts are normal tissue cells that melanoma corrupts into allies. Once hijacked, these fibroblasts restructure the surrounding tissue, secrete growth factors that promote tumor expansion and blood-vessel formation, and create chemical conditions that suppress incoming immune cells.35PubMed Central. Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma They also help organize distant “pre-metastatic niches,” essentially preparing soil in other organs where melanoma cells can land and take root.36PubMed Central. The Role of Fibroblasts in Melanoma Development: From Tumor Microenvironment Remodeling to Pre-Metastatic Niche Formation Understanding these interactions has opened a new front in treatment research: rather than targeting only the melanoma cells, disrupting the supportive microenvironment could make tumors more vulnerable to both drugs and the immune system. Experimental strategies aimed at blocking the cross-talk between fibroblasts and melanoma cells have shown the ability to suppress tumor growth in laboratory models, though translating that into approved therapies remains a work in progress.